<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112078</article-id><article-id pub-id-type="publisher-id">ACM-40455</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_55162569.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  体重指数对评估硼替佐米治疗多发性骨髓瘤周围神经病变发生的价值
  The Value of Body Mass Index in Evaluating the Occurrence of Peripheral Neuropathy in Patients with Multiple Myeloma Treated with Bortezomib
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>金铭</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>潍坊医学院临床医学院，山东 潍坊</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>542</fpage><lpage>546</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：研究体重指数(Body Mass Index, BMI)在评估硼替佐米治疗多发性骨髓瘤(Multiple Myeloma, MM)中发生周围神经病变(Peripheral Neuropathy, PN)的价值。方法：随机抽样的方法选取潍坊医学院附属医院收治的以硼替佐米为中心治疗的MM患者80例，采集初诊时患者信息，观察并记录患者治疗期间及治疗后硼替佐米相关周围神经病变(Bortezomib-induced peripheral neuropathy, BIPN)的发生情况，进行相关的统计学分析。结果：80例患者中，28例出现BIPN (35%)，且BIPN组BMI高于非BIPN组(P &lt; 0.05)，超重及肥胖组BMI与BIPN的发生率呈正相关(P &lt; 0.05)，而对于BMI &lt;24 kg/m2的患者，体重指数与PN的发生无明显意义(P &gt; 0.05)。结论：在硼替佐米治疗MM过程中，BMI可能与BIPN的发生有关。
    Objective: The aim of the study was to investigate the value of body mass index in evaluating peripheral neuropathy in patients with multiple myeloma treated with bortezomib. Methods: 80 cases of MM patients treated with bortezomib in the Affiliated Hospital of Weifang Medical University were selected by random sampling method. Collectedthe information of patients at the initial diagnosis, and the occurrence of bortezomib related peripheral neuropathy during and after the treatment was observed and recorded for relevant statistical analysis. Results: Among the 80 patients, 28 cases (35%) had BIPN, and the BMI of BIPN group was higher than that of non-BIPN group (P &lt; 0.05). The BMI of overweight and obesity group was positively correlated with the incidence of BIPN (P &lt; 0.05), but for patients with BMI &lt; 24 kg/m2, there was no significant difference between BMI and the incidence of BIPN (P &gt; 0.05). Conclusion: In the course of bortezomib treatment of MM, BMI may be related to the occurrence of BIPN. 
  
 
</p></abstract><kwd-group><kwd>体重指数，硼替佐米，多发性骨髓瘤，周围神经病变, Body Mass Index</kwd><kwd> Bortezomib</kwd><kwd> Multiple Myeloma</kwd><kwd> Peripheral Neuropathy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：研究体重指数(Body Mass Index, BMI)在评估硼替佐米治疗多发性骨髓瘤(Multiple Myeloma, MM)中发生周围神经病变(Peripheral Neuropathy, PN)的价值。方法：随机抽样的方法选取潍坊医学院附属医院收治的以硼替佐米为中心治疗的MM患者80例，采集初诊时患者信息，观察并记录患者治疗期间及治疗后硼替佐米相关周围神经病变(Bortezomib-induced peripheral neuropathy, BIPN)的发生情况，进行相关的统计学分析。结果：80例患者中，28例出现BIPN (35%)，且BIPN组BMI高于非BIPN组(P &lt; 0.05)，超重及肥胖组BMI与BIPN的发生率呈正相关(P &lt; 0.05)，而对于BMI &lt;24 kg/m<sup>2</sup>的患者，体重指数与PN的发生无明显意义(P &gt; 0.05)。结论：在硼替佐米治疗MM过程中，BMI可能与BIPN的发生有关。</p></sec><sec id="s2"><title>关键词</title><p>体重指数，硼替佐米，多发性骨髓瘤，周围神经病变</p></sec><sec id="s3"><title>The Value of Body Mass Index in Evaluating the Occurrence of Peripheral Neuropathy in Patients with Multiple Myeloma Treated with Bortezomib<sup> </sup></title><p>Jinming Xiao</p><p>Clinical Medicine College, Weifang Medical University, Weifang Shandong</p><p><img src="//html.hanspub.org/file/17-1571943x4_hanspub.png" /></p><p>Received: Jan. 17<sup>th</sup>, 2021; accepted: Feb. 2<sup>nd</sup>, 2021; published: Feb. 20<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/17-1571943x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The aim of the study was to investigate the value of body mass index in evaluating peripheral neuropathy in patients with multiple myeloma treated with bortezomib. Methods: 80 cases of MM patients treated with bortezomib in the Affiliated Hospital of Weifang Medical University were selected by random sampling method. Collectedthe information of patients at the initial diagnosis, and the occurrence of bortezomib related peripheral neuropathy during and after the treatment was observed and recorded for relevant statistical analysis. Results: Among the 80 patients, 28 cases (35%) had BIPN, and the BMI of BIPN group was higher than that of non-BIPN group (P &lt; 0.05). The BMI of overweight and obesity group was positively correlated with the incidence of BIPN (P &lt; 0.05), but for patients with BMI &lt; 24 kg/m<sup>2</sup>, there was no significant difference between BMI and the incidence of BIPN (P &gt; 0.05). Conclusion: In the course of bortezomib treatment of MM, BMI may be related to the occurrence of BIPN.</p><p>Keywords:Body Mass Index, Bortezomib, Multiple Myeloma, Peripheral Neuropathy</p><disp-formula id="hanspub.40455-formula19"><graphic xlink:href="//html.hanspub.org/file/17-1571943x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/17-1571943x7_hanspub.png" /> <img src="//html.hanspub.org/file/17-1571943x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>多发性骨髓瘤(Multiple Myeloma, MM)是一种由单克隆浆细胞恶性增值并广泛浸润引起的恶性浆细胞疾病，目前病因尚不明确，中老年人多见，性别差异显著，男:女 = 1.5~2:1，发病率位居血液学恶性肿瘤第二位，且近年来有发病率不断上升的趋势 [<xref ref-type="bibr" rid="hanspub.40455-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40455-ref2">2</xref>]。主要表现为骨痛、反复持续的感染、贫血、肾功能损害等 [<xref ref-type="bibr" rid="hanspub.40455-ref3">3</xref>]。现阶段针对多发性骨髓瘤的治疗方案主要以蛋白酶体抑制剂硼替佐米为一线用药 [<xref ref-type="bibr" rid="hanspub.40455-ref4">4</xref>]，其抗肿瘤作用较强、临床疗效较好、克服耐药缺点且价格适中，为多发性骨髓瘤患者带来了福音 [<xref ref-type="bibr" rid="hanspub.40455-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.40455-ref6">6</xref>]。硼替佐米的常见不良反应主要有骨髓抑制、周围神经病变等，其中PN发生率高、生存质量降低，且会导致用药剂量减少、更换替代治疗方案甚至治疗中断 [<xref ref-type="bibr" rid="hanspub.40455-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40455-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40455-ref9">9</xref>]，严重影响患者的治疗及预后，近年来得到越来越多的关注。如何更好的评估和预防PN，提高MM患者的治疗效果及生存质量，有待进一步探究，本文主要探讨体重指数这一指标对评估BIPN发生率的意义。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 基础资料</title><p>本研究为回顾性单中心研究，研究对象选取潍坊医学院附属医院2015年至2020年期间收治的应用硼替佐米治疗多发性骨髓瘤的患者80例。本研究经医院伦理委员审核批准。列入本研究的患者均满足以下条件：1) 纳入研究的MM患者符合国际骨髓瘤协作组(IMWG)关于MM的诊断标准 [<xref ref-type="bibr" rid="hanspub.40455-ref10">10</xref>]，且排除合并严重心、肺功能异常及其他重大疾病患者。2) 均接受至少一个完整周期的方案治疗。3) 均为之前未经其他治疗的、新诊断的多发性骨髓瘤患者。4) 硼替佐米采用皮下注射途径。5) 患者均根据患者实际体重接受硼替佐米的剂量。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>根据BMI计算公式：BMI = 体重/身高的平方(国际单位kg/m<sup>2</sup>)，按照BMI分类的世界卫生组织标准将患者分为以下3组：低体重(BMI &lt; 18.5)、体重正常(18.5 ≤ BMI &lt; 24)、超重及肥胖(BMI ≥ 24)。患者的周围神经病变依据美国国立癌症研究所通用毒性标准(NCI CT-CAE4.0)进行诊断。</p></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>计算周围神经病变的发生率，利用统计分析的方法分析体重指数与周围神经病变发生的相关性。对采集过程记录的数据均采用SPSS 22.0软件进行统计学的处理和分析，正态分布的计量资料采用t检验分析，非正态分布的计数资料采用秩和检验，采用Spearman检验相关性，分析体重指数评估周围神经病变发生的价值，P &lt; 0.05认为有显著的统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 患者一般资料</title><p>本研究收集80例应用硼替佐米治疗MM的患者，年龄50~82岁，平均63.4 &#177; 4.2岁，按入院时BMI将病人分为低体重组15例、正常体重组37例、超重及肥胖组28例。其中有28例患者出现BIPN，占35%，低体重组4例(14%)，正常体重组9例(32%)，超重及肥胖组15例(54%)。</p></sec><sec id="s7_2"><title>3.2. 回归分析与BIPN发生率相关的影响因素</title><p>将对可能影响BIPN发生的相关危险因素纳入分析：性别、年龄、是否吸烟、ISS分期、浆细胞比值、白蛋白、肌酐、β<sub>2</sub>微球蛋白、乳酸脱氢酶、体重指数设为自变量，以是否发生CIPN为因变量，进行二元Logistic回归分析。分析结果显示，BMI与BIPN发生率有影响(P &lt; 0.05)，余性别、年龄、是否吸烟、ISS分期、浆细胞比值、白蛋白、肌酐、β<sub>2</sub>微球蛋白、乳酸脱氢酶均未显示对BIPN的发生率有显著影响(P &gt; 0.05)，由此得出，在硼替佐米治疗MM的患者中，BIPN发生的影响因素可能是体重指数，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Results of Logistic regression analysis of influencing factors of BIP</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >自变量</th><th align="center" valign="middle"  rowspan="2"  >B</th><th align="center" valign="middle"  rowspan="2"  >Wald</th><th align="center" valign="middle"  rowspan="2"  >P值</th><th align="center" valign="middle"  rowspan="2"  >Exp (B)</th><th align="center" valign="middle"  colspan="2"  >95% EXP (B)之信赖区间</th></tr></thead><tr><td align="center" valign="middle" >下限</td><td align="center" valign="middle" >上限</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >0.578</td><td align="center" valign="middle" >0.627</td><td align="center" valign="middle" >0.428</td><td align="center" valign="middle" >1.783</td><td align="center" valign="middle" >0.426</td><td align="center" valign="middle" >7.457</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.033</td><td align="center" valign="middle" >0.538</td><td align="center" valign="middle" >0.463</td><td align="center" valign="middle" >1.034</td><td align="center" valign="middle" >0.946</td><td align="center" valign="middle" >1.130</td></tr><tr><td align="center" valign="middle" >吸烟</td><td align="center" valign="middle" >0.508</td><td align="center" valign="middle" >0.535</td><td align="center" valign="middle" >0.464</td><td align="center" valign="middle" >1.662</td><td align="center" valign="middle" >0.426</td><td align="center" valign="middle" >6.474</td></tr><tr><td align="center" valign="middle" >临床分期</td><td align="center" valign="middle" >0.347</td><td align="center" valign="middle" >0.766</td><td align="center" valign="middle" >0.381</td><td align="center" valign="middle" >1.414</td><td align="center" valign="middle" >0.651</td><td align="center" valign="middle" >3.075</td></tr><tr><td align="center" valign="middle" >浆细胞</td><td align="center" valign="middle" >−0.015</td><td align="center" valign="middle" >0.732</td><td align="center" valign="middle" >0.392</td><td align="center" valign="middle" >0.985</td><td align="center" valign="middle" >0.951</td><td align="center" valign="middle" >1.020</td></tr><tr><td align="center" valign="middle" >白蛋白</td><td align="center" valign="middle" >0.016</td><td align="center" valign="middle" >0.131</td><td align="center" valign="middle" >0.717</td><td align="center" valign="middle" >1.016</td><td align="center" valign="middle" >0.932</td><td align="center" valign="middle" >1.107</td></tr><tr><td align="center" valign="middle" >微球蛋白</td><td align="center" valign="middle" >−0.084</td><td align="center" valign="middle" >1.463</td><td align="center" valign="middle" >0.226</td><td align="center" valign="middle" >0.920</td><td align="center" valign="middle" >0.803</td><td align="center" valign="middle" >1.053</td></tr><tr><td align="center" valign="middle" >肌酐</td><td align="center" valign="middle" >0.007</td><td align="center" valign="middle" >1.440</td><td align="center" valign="middle" >0.230</td><td align="center" valign="middle" >1.007</td><td align="center" valign="middle" >0.996</td><td align="center" valign="middle" >1.018</td></tr><tr><td align="center" valign="middle" >LDH</td><td align="center" valign="middle" >−0.014</td><td align="center" valign="middle" >1.542</td><td align="center" valign="middle" >0.214</td><td align="center" valign="middle" >0.986</td><td align="center" valign="middle" >0.964</td><td align="center" valign="middle" >1.008</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >0.853</td><td align="center" valign="middle" >4.608</td><td align="center" valign="middle" >0.032</td><td align="center" valign="middle" >2.347</td><td align="center" valign="middle" >1.077</td><td align="center" valign="middle" >5.114</td></tr></tbody></table></table-wrap><p>表1. BIPN影响因素的Logistic回归分析结果</p></sec><sec id="s7_3"><title>3.3. BIPN组和非BIPN组体重指数比较</title><p>秩和等级检验显示，两组患者BMI水平比较，BIPN组高体重患者明显多于非BIPN组，且差异有统计学意义(P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of BMI between BIPN group and non-BIPN grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >低体重</th><th align="center" valign="middle" >体重正常</th><th align="center" valign="middle" >超重及肥胖</th><th align="center" valign="middle" >Z值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >BIPN组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >15</td><td align="center" valign="middle"  rowspan="2"  >−2.202</td><td align="center" valign="middle"  rowspan="2"  >0.028</td></tr><tr><td align="center" valign="middle" >非BIPN组</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >13</td></tr></tbody></table></table-wrap><p>表2. BIPN组和非BIPN组体重指数比较</p></sec><sec id="s7_4"><title>3.4. 不同组体重指数患者与BIPN发生相关性比较</title><p>利用Spesrman方法进行相关性分析，分析不同等级体重指数与BIPN发生的相关性，结果显示，患者用药前的体重指数与周围神经病变的发生有相关性(P &lt; 0.05)，且对于体重指数 ≥ 24 kg/m<sup>2</sup>的患者，体重指数与BIPN的发生率呈正相关，而对于低体重组及正常体重组的患者，体重指数与BIPN的发生无明显意义，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation between BMI and BIPN in different group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >低体重</th><th align="center" valign="middle" >体重正常</th><th align="center" valign="middle" >超重及肥胖</th></tr></thead><tr><td align="center" valign="middle" >BIPN</td><td align="center" valign="middle" >4例(27%)</td><td align="center" valign="middle" >9例(24%)</td><td align="center" valign="middle" >15例(28%)</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.100</td><td align="center" valign="middle" >0.986</td><td align="center" valign="middle" >0.042</td></tr><tr><td align="center" valign="middle" >rs</td><td align="center" valign="middle" >0.441</td><td align="center" valign="middle" >−0.03</td><td align="center" valign="middle" >0.387</td></tr></tbody></table></table-wrap><p>表3. 不同组体重指数患者与BIPN发生相关性</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>周围神经病变是周围神经损伤引起的远端对称多神经病变，包括感觉、运动以及自主神经病变。BIPN最常见的是感觉神经受损，主要表现为远端肢体感觉异常和袜套样感觉缺失，静息状态可引起急剧的周围神经痛 [<xref ref-type="bibr" rid="hanspub.40455-ref11">11</xref>]。有研究表明，硼替佐米所致PN呈剂量依赖性，且具有可逆性，大部分患者在调整剂量或停药后症状都可以得到不同程度的缓解 [<xref ref-type="bibr" rid="hanspub.40455-ref12">12</xref>]。BIPN的机制可能与多种路径有关，包括硼替佐米通过调节腰椎脊髓及背根神经节的蛋白激酶通路，导致神经元细胞内出现嗜酸物质沉积和染色质的溶解，诱导PN发生；通过促进内质网中钙离子的释放增多，激活caspase-12，导致线粒体和内质网损伤；也可能与基因异常、肿瘤坏死因子表达增加有关 [<xref ref-type="bibr" rid="hanspub.40455-ref13">13</xref>]。周围神经病变的相关危险因素尚不明确，本研究显示体重指数与PN的发生密切相关，肥胖患者的脂肪组织可分泌大量细胞因子，有研究表明，肥胖患者的白介素-6水平明显高于正常人，而CD4+细胞亚群失衡导致Th2细胞分泌的高水平IL-6与神经病理性疼痛相关。同时，肥胖患者体内高水平的瘦素、脂联素等脂肪因子可引起代谢综合征，可引起脂肪酸氧化、脂质代谢紊乱，也可导致血管损伤从而进一步引起神经组织的结构和功能损害 [<xref ref-type="bibr" rid="hanspub.40455-ref14">14</xref>]。</p><p>综上所述，对于应用硼替佐米治疗多发性骨髓瘤的患者，体重指数可能对评估化疗相关周围神经病变的发生有一定价值，且对于BMI ≥ 24 kg/m<sup>2</sup>的患者，体重指数与BIPN的发生率呈正相关，值得注意的是，体重指数作为可调节指标，作者认为对临床治疗有一定的指导价值，成年多发性骨髓瘤患者应尽量将体重指数控制在正常范围内，而对于MM患者是否可以应用药物控制体重指数尚需考证。本研究仍存在研究时间较短及样本数较少的缺点，需在今后进一步延长随访时间及扩大样本数量，从而做出更好的分析。</p></sec><sec id="s9"><title>文章引用</title><p>肖金铭. 体重指数对评估硼替佐米治疗多发性骨髓瘤周围神经病变发生的价值The Value of Body Mass Index in Evaluating the Occurrence of Peripheral Neuropathy in Patients with Multiple Myeloma Treated with Bortezomib[J]. 临床医学进展, 2021, 11(02): 542-546. https://doi.org/10.12677/ACM.2021.112078</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40455-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Greenlee, M.R.T., Murray, M.T., Bolden, M.S., et al. (2000) Cancer Statistics, 2000. CA: A Cancer Journal for Clinicians, 50, 7-33. https://doi.org/10.3322/canjclin.50.1.7</mixed-citation></ref><ref id="hanspub.40455-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hofmann, J.N., Moore, S.C., Unhee, L., et al. (2013) Body Mass Index and Physical Activity at Different Ages and Risk of Multiple Myeloma in the NIH-AARP Diet and Health Study. American Journal of Epidemiology, 177, 776-786.  
https://doi.org/10.1093/aje/kws295</mixed-citation></ref><ref id="hanspub.40455-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bosseboeuf, A., Feron, D., Tallet, A., et al. (2017) Monoclonal IgG in MGUS and Multiple Myeloma Targets Infectious Pathogens. JCI Insight, 2, 19. https://doi.org/10.1172/jci.insight.95367</mixed-citation></ref><ref id="hanspub.40455-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, S.K., Callander, N.S., Alsina, M., et al. (2017) Multiple Myeloma, Version 3. 2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15, 230-269.  
https://doi.org/10.6004/jnccn.2017.0023</mixed-citation></ref><ref id="hanspub.40455-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">秦慧, 汪延生, 丁士华, 等. 皮下注射硼替佐米治疗多发性骨髓瘤的疗效及安全性分析[J]. 四川大学学报: 医学版, 2014, 45(3): 529-532.</mixed-citation></ref><ref id="hanspub.40455-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kaplan, G.S., Torcun, C.C., Grune, T., et al. (2016) Proteasome Inhibitors in Cancer Therapy: Treatment Regimen and Peripheral Neuropathy as a Side Effect. Free Radical Biology &amp; Medicine, 103, 1-13.  
https://doi.org/10.1016/j.freeradbiomed.2016.12.007</mixed-citation></ref><ref id="hanspub.40455-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Broy, A. (2010) Development of Bortezomib Induced Peripheral Neuropathy (BiPN) in Multiple Myeloma: Incidence and Molecular Characterization in Newly Diagnosed Patients Treated with Bortezomib. Blood, 116, 304.  
https://doi.org/10.1182/blood.V116.21.304.304</mixed-citation></ref><ref id="hanspub.40455-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lakshman, A., Modi, M., Prakash, G., et al. (2017) Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib-Based Induction. Clinical Lymphoma Myeloma &amp; Leukemia, 17, 513-519.  
https://doi.org/10.1016/j.clml.2017.06.035</mixed-citation></ref><ref id="hanspub.40455-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Song, X., Wilson, K.L., Kagan, J., et al. (2019) Cost of Peripheral Neuropathy in Patients Receiving Treatment for Multiple Myeloma: A US Administrative Claims Analysis. Therapeutic Advances in Hematology, 10, 746-751. 
https://doi.org/10.1177/2040620719839025</mixed-citation></ref><ref id="hanspub.40455-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">International Myeloma Working Group (2003) Criteria for the Classification of Monoclonal Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757. https://doi.org/10.1046/j.1365-2141.2003.04355.x</mixed-citation></ref><ref id="hanspub.40455-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Delforge, M., Bladé, J., Dimopoulos, M.A., et al. (2010) Treatment-Related Peripheral Neuropathy in Multiple Myeloma: The Challenge Continues. Lancet Oncology, 11, 1086-1095. https://doi.org/10.1016/S1470-2045(10)70068-1</mixed-citation></ref><ref id="hanspub.40455-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cho, J., Kang, D., Lee, J.Y., et al. (2014) Impact of Dose Modification on Intravenous Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patient. Supportive Care in Cancer, 22, 2669-2675.  
https://doi.org/10.1007/s00520-014-2256-6</mixed-citation></ref><ref id="hanspub.40455-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">陆晓萱, 颜晓菁. 硼替佐米诱发周围神经病变发病机制的研究进展[J]. 现代肿瘤医学, 2020, 28, 305(23): 156-161.</mixed-citation></ref><ref id="hanspub.40455-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ravaglia, S., Corso, A., Piccolo, G., et al. (2008) Immune-Mediated Neuropathies in Myeloma Patients Treated with Bortezomib. Clinical Neurophysiology Official Journal of the International Federation of Clinical Neurophysiology, 119, 2507-2512. https://doi.org/10.1016/j.clinph.2008.08.007</mixed-citation></ref></ref-list></back></article>